CDC25A and hepatocellular carcinoma: This indicates that H19 can be used to assess the prognosis of HCC.154 But, there are reports where H19 expression is decreased in HCC,153, 154 and reflect poor prognostic outcomes.153 Other studies implicated H19 in the activation of miR‐200 and suppression of EMT process and tumor metastasis.153 In a study where miR‐675 was used to inhibit H19, results showed that this enhanced metastasis of HCC through the AKT/GSK‐3beta/Cdc25A pathway.149 To this end, it can be concluded that H19 mediates a suppressive effect on tumors and may be an oncogene in HCC.